Monday, February 7, 2022 @ Noon Pacific, 1 pm Mountain, 2 pm Central, 3 pm Eastern
Dr. Robert Z. Orlowski joins Myeloma Crowd Radio to share a study to share the new innovations myeloma patients can expect in 2022. He will review the recent findings from the American Society of Hematology meeting and share what we can expect from new combination therapies, best options for newly diagnosed myeloma patients, expected FDA approvals in 2022, CAR T advances, bispecific and trispecific antibodies, antibody drug conjugates, targeted inhibitors and new approaches for MGUS and smoldering myeloma. We invite you to join us for this well loved annual show.
Dr. Orlowski is Chairman, Ad Interim, Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics, Division of Cancer Medicine at MD Anderson Cancer Center. Dr. Orlowski serves as Chair of the Southwest Oncology Group (SWOG) and is a member of the NCI Steering Committee, the Multiple Myeloma Tissue Bank Steering Committee, the Computerized Provider Order Entry Steering Committee, BMT Committee, and American Society for Biochemistry and Molecular Biology. Dr. Orlowski is on the Editorial Board of Hematology and the Journal of Clinical Oncology. Dr. Orlowski has received many awards over a number of years including the Leukemia & Lymphoma Society Scholar in Clinical Research, the Leukemia & Lymphoma Society’s Man of the Year Award, Emil Frei III Award for Excellence in Translational Research from MD Anderson and is the recipient of an ongoing SPORE grant from the NIH. Find news and information from his daily newspaper, Myeloma Daily or find him on Twitter at @myeloma_doc.
Thanks to our episode sponsor, Bristol Myers Squibb
about the author
Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of HealthTree Foundation (formerly Myeloma Crowd).